KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Common Equity (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Common Equity for 15 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 2.51% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 2.51% increase, with the full-year FY2025 number at $1.1 billion, up 2.51% from a year prior.
  • Common Equity was $1.1 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.1 billion in Q2 2025 to a low of $754.4 million in Q1 2021.
  • A 5-year average of $914.2 million and a median of $912.2 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: grew 23.0% in 2021, then rose 1.87% in 2024.
  • Supernus Pharmaceuticals' Common Equity stood at $815.9 million in 2021, then grew by 8.62% to $886.2 million in 2022, then grew by 3.98% to $921.5 million in 2023, then rose by 12.39% to $1.0 billion in 2024, then grew by 2.51% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Common Equity are $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.1 billion (Q2 2025).